Ocular Hypertension (Elevated Eye Pressure) Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceMay help improve blood flow to optic nerve and reduce inflammation
Anthocyanins support ocular blood flow and may have neuroprotective effects
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsAntioxidant; some studies suggest high doses may lower IOP
Supporting Studies (1)
May improve blood flow to optic nerve; muscle relaxation effects
Supporting Studies (1)
Improves microcirculation and may protect optic nerve
Supporting Studies (1)
Mitochondrial support; may protect retinal ganglion cells
Supporting Studies (1)
Antioxidant that may protect ocular tissues from oxidative damage
Supporting Studies (1)
Antioxidant protection for ocular tissues
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Ocular hypertension is elevated eye pressure (intraocular pressure/IOP) without any damage to the optic nerve or visual field loss. Normal IOP is 10-21 mmHg; ocular hypertension is typically defined as IOP >21 mmHg. It's important because elevated IOP is the main risk factor for glaucoma, a disease that damages the optic nerve and causes irreversible vision loss. However, not everyone with ocular hypertension develops glaucoma - only about 10% over 5 years without treatment.
CRITICAL: Ocular hypertension requires monitoring by an eye doctor (ophthalmologist or optometrist). Regular comprehensive eye exams including IOP measurement, optic nerve examination, and visual field testing are essential. Treatment decisions depend on IOP level, optic nerve appearance, visual field, corneal thickness, family history, and other risk factors. If treatment is needed, prescription eye drops (prostaglandin analogs, beta-blockers, etc.) are the mainstay. These supplements may support eye health but are NOT a replacement for prescribed IOP-lowering medications if indicated.
* Omega-3 Fatty Acids may support blood flow to the optic nerve and reduce inflammation. Some studies show an association between dietary omega-3 intake and lower glaucoma risk.
* Bilberry Extract contains anthocyanins that support ocular blood flow and may have neuroprotective effects for the optic nerve.
* Vitamin C is an antioxidant found in high concentrations in the aqueous humor. Some older studies suggest high doses may temporarily lower IOP.
* Magnesium may improve blood flow to the optic nerve and has shown some benefit in glaucoma studies.
* Ginkgo Biloba improves microcirculation and may have neuroprotective effects for the optic nerve.
* Coenzyme Q10 supports mitochondrial function in retinal ganglion cells.
* Alpha-Lipoic Acid provides antioxidant protection.
Expected timeline: These supplements support long-term eye health. They are not expected to significantly lower IOP like prescription medications. Regular monitoring every 6-12 months is essential.
Clinical Perspective
Ocular hypertension (OHT): IOP >21 mmHg without glaucomatous optic neuropathy or visual field loss. Prevalence: 4-10% of adults over 40. Natural history: ~10% develop glaucoma at 5 years (untreated); higher risk with higher IOP, thinner cornea, older age, family history, larger cup-to-disc ratio. OHTS study showed treatment reduces progression to glaucoma by ~50%.
CRITICAL: Evaluation: comprehensive eye exam including IOP (Goldmann applanation), gonioscopy (rule out angle closure), pachymetry (central corneal thickness - thin cornea = higher risk), optic nerve assessment (cup-to-disc ratio, RNFL), visual field testing. Treatment decision: based on risk assessment - consider treating if IOP >24-26, thin CCT, suspicious optic nerve, strong family history. First-line treatment: prostaglandin analog drops. Target: 20-25% IOP reduction. Supplements are ADJUNCTIVE - not replacement for prescribed treatment.
* Omega-3 Fatty Acids (C-grade): Optic nerve support; anti-inflammatory. Systematic review: glaucoma (PMID: 26932548). Study: IOP association (PMID: 29046251). 2-3g EPA+DHA daily.
* Bilberry (C-grade): Anthocyanins; blood flow. Review: glaucoma (PMID: 25109868). 160-320mg extract daily.
* Vitamin C (C-grade): Aqueous humor antioxidant. Review: IOP effects (PMID: 12180839). 500-1000mg daily.
* Magnesium (C-grade): Vasodilation; neuroprotection. Clinical trial: glaucoma (PMID: 8780223). 300-400mg daily.
* Ginkgo Biloba (C-grade): Microcirculation; neuroprotection. Systematic review: glaucoma (PMID: 23869991). 120-240mg extract daily.
* CoQ10 (C-grade): Mitochondrial support. Review: glaucoma (PMID: 25209680). 100-200mg daily.
* Alpha-Lipoic Acid (C-grade): Antioxidant. Review: (PMID: 26000973). 300-600mg daily.
* Vitamin E (D-grade): Antioxidant. Review: glaucoma (PMID: 16936087). 200-400 IU daily.
Biomarker targets: IOP (goal varies by individual; 10-21 mmHg general target), optic nerve appearance (stable), visual field (stable), RNFL thickness (OCT).
Protocol notes: Lifestyle: moderate exercise may lower IOP; avoid head-down positions (yoga inversions); caffeine in moderation. Avoid: large fluid intake at once (can raise IOP); tight neckwear. Diet: leafy greens (nitrates may help); antioxidant-rich foods. Sleep: sleep apnea associated with glaucoma - treat if present. Medications to review: steroids (can raise IOP); anticholinergics. Monitoring: IOP checks q6-12 months; visual field and OCT annually or as indicated. Converting to glaucoma: treated as open-angle glaucoma with IOP-lowering medications, laser (SLT), or surgery if needed. Supplements: inform eye doctor; no strong evidence they lower IOP significantly but may support overall eye health. Normal-tension glaucoma: can occur even with 'normal' IOP - optic nerve damage determines diagnosis, not IOP alone.